MediPharm Labs Corp. (TSXV:LABS, OTCQB:MEDIF, FSE:MLZ)(“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce the appointment of Braden Fenske as Chief Strategy Officer effective April 29, 2019.  In this newly created executive role, Mr. Fenske will be responsible for advancing the Company’s strategic corporate initiatives in collaboration with the Company’s executives and operational teams across the company. Leveraging his extensive relationships within the healthcare industry, Mr. Fenske will also focus on accelerating domestic and global growth and expanding strategic partnerships to create additional value and opportunities for MediPharm Labs’ new products and growing portfolio of cannabis and non-cannabis customers.

Mr. Fenske brings to the Company 20 years of diverse and highly specialized experience within the global healthcare industry and prior to that the adult beverage industry. Over a 15-year career with the Johnson & Johnson Group of Companies (“J&J”), Mr. Fenske has developed unique and extensive experience within the pharmaceutical and medical device sectors leading product development, marketing, global strategy and operations that spanned multiple therapeutic areas in the U.S. and among global healthcare markets. Most recently, Mr. Fenske served as Group Product Director, Global Strategic Marketing for Biosense Webster Inc., a J&J Company. He managed J&J’s Medical Devices’ “next billion-dollar new product launch” upon its FDA approval in the USA and CE mark in Europe.  Mr. Fenske’s previous experience with Mark Anthony Brands Inc. and Molson Coors Brewing Co. also provides unique insights into the recreational consumer and the burgeoning edibles and cannabis based derivative product segments.


“We are thrilled to have Braden join our team at this pivotal moment in our history. With our leading extraction industry performance and momentum, our expanding portfolio of products, increasing customer base and deep pipeline of growth opportunities, we have demonstrated a clear potential for accelerated revenue growth,” said Patrick McCutcheon, Chief Executive Officer, MediPharm Labs. “Braden’s proven record of success developing operational growth strategies, his unique understanding of the pharmaceutical and medical delivery systems industry, and his U.S. and worldwide healthcare relationships, will strengthen MediPharm Labs’ position as a trusted partner for customers, and clinical trials, as we remain at the leading edge of the industry and achieve our growth potential in this rapidly evolving market.”

“I am excited to be joining the MediPharm Labs’ team positioned at the forefront of this quickly evolving industry with demand for purified concentrates driving growth and innovation,” said Braden Fenske, Chief Strategy Officer, MediPharm Labs.  “I have been impressed by the depth and caliber of the talented management team, and the Company’s compelling platform to be the dominant provider of scaled cannabinoid based derivative products for medical and recreational consumers globally. I look forward to working alongside these outstanding leaders to elevate MediPharm Labs’ position as a trusted partner and deliver our next stage of exponential growth.”

About Braden Fenske, Chief Strategy Officer

Braden joins MediPharm Labs from Johnson & Johnson Group of Companies, bringing over 20 years of experience in diverse strategic, commercial, new product planning, and business development roles predominantly in Pharmaceuticals and Medical Devices industries.

Most recently, Braden served as Group Product Director, Global Strategic Marketing for Biosense Webster Inc., a J&J Company, with more than 1,300 professionals in 40 countries around the world, recognized worldwide as a leader in the science behind the diagnosis and treatment of cardiac arrhythmias.  At Biosense Webster, he led the strategy and execution of J&J’s “most important New Product launch in the last decade” and facilitated product development from Research & Development through to commercial launch.

In his 15-year career with J&J in Canada and the USA (J&J Medical Devices, Biosense Webster Inc., Janssen Inc.), Braden held progressive roles on an accelerated leadership path and was highly awarded with multiple wins in President’s & Performance Clubs, Standards of Leadership and President’s Innovation.

During his tenure with J&J, Braden also led various global marketing initiatives for medical devices, driving corporate strategy and innovative product launches to optimize market share and revenue. Earlier in his career, Braden worked at both Mark Anthony Brands Inc. and Molson Coors Brewing Co. with leadership development roles in sales, marketing and trade promotions. Braden holds a Bachelor of Commerce degree from the University of Alberta.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-like cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the Company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

For further information, please contact:
Investor Relations & Communications
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding an expanding portfolio of products, accelerating domestic and global growth, expanding key strategic partnerships, a growing portfolio of cannabis and non-cannabis customers, an increasing customer base, a deep pipeline of growth opportunities,  accelerated revenue growth, GMP certification, and the establishment of operations in Australia. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals: and other factors discussed in the Company’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

An Emerging Markets Sponsored Commentary

A report just released in early April confirms that the cannabis beverage sector is thriving. According to this report from industry stalwart, Marijuana Business Daily while sales for vapes, pre-rolls and flower were lackluster, cannabis beverages shined:

Keep reading... Show less

BevCanna Enterprises (CSE:BEV,OTCQQ:BVNNF,FWB:7BC) CEO Marcello Leone shared how the company is scaling up its products to forge partnerships and explore opportunities across Canada, the US and Western Europe. 

“Getting your standard processing license and being fully compliant at a federal level is critical in Canada, and we were successful in getting that done. Now we’re getting ready to launch our Keef line of beverages within the next 45 days,” Leone said. 

As a young company, Leone said BevCanna has only started, but it took a four-pronged approach to make sure that it is a revenue-generating company prepared for the opening of many jurisdictions for CBD-based products.

“We are blessed that we have a beautiful infrastructure of our own, a state-of-the-art bottling facility with a capacity of almost 200 million bottles per annum and a strong balance sheet of $55 million. We are in a strong position to scale and grow this company.”

BevCanna has received a Standard Processing License from Health Canada and is now fully authorized to begin production at its full-service, high-capacity beverage manufacturing facility. The company will begin production of its white-label products, number one US cannabis beverage brand Keef and its in-house beverages through licensed Canadian retailers, positioning the company to fully capitalize on the burgeoning Canadian cannabis-infused beverage sector.

Watch the full interview with CEO Marcello Leone above.

Keep reading... Show less

BioHarvest Sciences (CSE: BHSC) will be presenting at the Benzinga Cleantech Small Cap Conference taking place on April 22, 2021. We invite our shareholders and all interested parties to explore cleantech small cap investment opportunities through two days of networking, dealmaking and discovery.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/clean-tech/

Keep reading... Show less

Positive distributor feedback and strong consumer interest accelerating launch with distributors

Emerging leader in innovative health and wellness beverages and products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that its wholly-owned subsidiary Naturo Group has successfully completed its initial shipment of TRACE plant-based products to one of Japan’s largest beverage distributors.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced an additional refreshment of its board of directors to further strengthen its leadership in the cannabis industry.

Keep reading... Show less